| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA1407963 |
| P698 | PubMed publication ID | 25234206 |
| P50 | author | Giuseppe Mancia | Q16560862 |
| Vlado Perkovic | Q28359591 | ||
| Sophia Zoungas | Q28359610 | ||
| Stephen Harrap | Q30519277 | ||
| Bruce Neal | Q37392165 | ||
| Michel Marre | Q37631006 | ||
| Simon Heller | Q38550003 | ||
| Paul Glasziou | Q38799353 | ||
| Pavel Hamet | Q3372940 | ||
| Stephen MacMahon | Q7609869 | ||
| Stephen Colagiuri | Q39619836 | ||
| Laurent Billot | Q42695957 | ||
| Anthony Rodgers | Q43042749 | ||
| John Chalmers | Q54269945 | ||
| Anushka Patel | Q58165563 | ||
| Hisatomi Arima | Q58517541 | ||
| Carl Erik Mogensen | Q62560222 | ||
| Diederick Grobbee | Q67409334 | ||
| Bryan Williams | Q90687501 | ||
| Yoichiro Hirakawa | Q91928773 | ||
| Rohina Joshi | Q92430426 | ||
| Neil R Poulter | Q92664402 | ||
| ADVANCE-ON Collaborative Group | Q116773574 | ||
| P2093 | author name string | David R Matthews | |
| Qiang Li | |||
| Mark Woodward | |||
| Liu Lisheng | |||
| Mark E Cooper | |||
| Helen Monaghan | |||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glucose | Q37525 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 1392-1406 | |
| P577 | publication date | 2014-09-19 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Follow-up of blood-pressure lowering and glucose control in type 2 diabetes | |
| P478 | volume | 371 |
| Q48556396 | 10th Annual Symposium on Self-Monitoring of Blood Glucose, April 27-29, 2017, Warsaw, Poland |
| Q90439418 | 5 Conservative treatment for PAD - Risk factor management |
| Q39014705 | 50 years forward: mechanisms of hyperglycaemia-driven diabetic complications |
| Q90428563 | A 7.0-7.7% value for glycated haemoglobin is better than a <7% value as an appropriate target for patient-centered drug treatment of type 2 diabetes mellitus |
| Q58593991 | ACCORDION: Ensuring That We Hear the Music Clearly |
| Q92309828 | Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes |
| Q58769905 | Age-related differences in glycaemic control, cardiovascular disease risk factors and treatment in patients with type 2 diabetes: a cross-sectional study from the Australian National Diabetes Audit |
| Q89523500 | Amelioration of arterial pressure lability: an unmissable target for diabetes management |
| Q38997456 | An update on DPP-4 inhibitors in the management of type 2 diabetes |
| Q53503168 | Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. |
| Q37604624 | Assessment of Human Tribbles Homolog 3 Genetic Variation (rs2295490) Effects on Type 2 Diabetes Patients with Glucose Control and Blood Pressure Lowering Treatment |
| Q35794324 | Assessment of Macular Peripapillary Nerve Fiber Layer and Choroidal Thickness Changes in Pregnant Women with Gestational Diabetes Mellitus, Healthy Pregnant Women, and Healthy Non-Pregnant Women |
| Q26740171 | Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion |
| Q38525956 | Benefit of Blood Pressure Control in Diabetic Patients |
| Q41584066 | Cardio-Metabolic Benefits of Plant-Based Diets |
| Q52571293 | Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. |
| Q26752255 | Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? |
| Q39420208 | Cardiovascular disease prevention strategies for type 2 diabetes mellitus |
| Q38902200 | Cardiovascular inflammation is reduced with methotrexate in diabetes |
| Q40405012 | Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. |
| Q64122759 | Cause-specific risk of major adverse cardiovascular outcomes and hypoglycemic in patients with type 2 diabetes: a multicenter prospective cohort study |
| Q91942084 | Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus |
| Q42368357 | Changes in treatment of hyperglycemia in a hypertensive type 2 diabetes population as renal function declines |
| Q37011769 | Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations |
| Q50198015 | Clinical features and therapeutic perspectives on hypertension in diabetics |
| Q39094213 | Clinical significance of 'cardiometabolic memory': a systematic review of randomized controlled trials |
| Q26752294 | Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation |
| Q41852283 | Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes |
| Q46441179 | Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline. |
| Q39310857 | Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis |
| Q40105411 | Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes |
| Q53497916 | Con: Biomarkers in glomerular diseases: putting the cart before the wheel? |
| Q35833486 | Control of Blood Pressure and Risk Attenuation: Post Trial Follow-Up of Randomized Groups |
| Q87887062 | Coronary artery disease severity modifies associations between glycemic control and both mortality and myocardial infarction |
| Q41136739 | Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S. |
| Q58778826 | Could Intensive Blood Pressure Control Really Reduce Diabetic Retinopathy Outcomes? Evidence from Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials |
| Q41991255 | Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes |
| Q57293899 | Defining Hypertension: Role of New Trials and Guidelines |
| Q38781550 | Developing Treatments for Chronic Kidney Disease in the 21st Century |
| Q59202592 | Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation |
| Q64242008 | Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults |
| Q91743110 | Diabetes Technology and Therapy in the Pediatric Age Group |
| Q41543509 | Diabetes: Dysglycaemia as a cause of cardiovascular outcomes |
| Q85901266 | Diabetes: Risks of strict glycaemic control in diabetic nephropathy |
| Q53133557 | Diabetes: Steno-2 - a small study with a big heart. |
| Q41983518 | Diabetic Kidney Disease: A Call to Action: Preface |
| Q43721013 | Diabetic kidney disease. |
| Q48048525 | Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy |
| Q38764131 | Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study. |
| Q43150121 | Dual therapy and diabetic kidney disease |
| Q26795773 | Dysglycemia after renal transplantation: Definition, pathogenesis, outcomes and implications for management |
| Q91593307 | ESVM Guideline on peripheral arterial disease |
| Q99355015 | Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME |
| Q43171798 | Editorial: Rethinking the definition of diabetes for precision medicine |
| Q35968414 | Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. |
| Q57822732 | Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice |
| Q47806448 | Endothelial APLNR regulates tissue fatty acid uptake and is essential for apelin's glucose-lowering effects |
| Q38747538 | Epigenetic Mechanisms in Diabetic Kidney Disease |
| Q38546855 | Ethnic disparities in risk of cardiovascular disease, end-stage renal disease and all-cause mortality: a prospective study among Asian people with Type 2 diabetes |
| Q38494441 | Extra-glycaemic properties of empagliflozin. |
| Q28079163 | Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity? |
| Q89537944 | Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence |
| Q52802931 | Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study. |
| Q30234704 | Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy |
| Q35748936 | Glycemic Control and Mortality in Diabetic Patients Undergoing Dialysis Focusing on the Effects of Age and Dialysis Type: A Prospective Cohort Study in Korea |
| Q41145183 | Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence |
| Q42330153 | Glycemic equipoise |
| Q57091823 | High-Intensity Interval Training Is Equivalent to Moderate-Intensity Continuous Training for Short- and Medium-Term Outcomes of Glucose Control, Cardiometabolic Risk, and Microvascular Complication Markers in Men With Type 2 Diabetes |
| Q96136057 | Hypoglycaemia and cardiac arrhythmias in diabetes |
| Q42376648 | Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. |
| Q37191370 | Improving Care in Older Patients with Diabetes: A Focus on Glycemic Control |
| Q60960130 | Intensive Glucose Control Reduces the Risk Effect of , and Genetic Variation on Diabetic Vascular Complications |
| Q92541792 | Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up |
| Q41335256 | Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation |
| Q90725902 | Legacy effect in medicine-the expanding horizon! |
| Q58593985 | Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes |
| Q38387633 | Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease: Results From the US Cohort of the International Verapamil (SR)/Trandolapril Study. |
| Q38420396 | Long-term effectiveness of a community-based model of care in Māori and Pacific patients with type 2 diabetes and chronic kidney disease: a 4-year follow up of the DElay Future End Stage Nephropathy due to Diabetes (DEFEND) study |
| Q40154695 | Long-term follow-up of a hospital-based, multi-intervention programme in type 2 diabetes mellitus: impact on cardiovascular events and death |
| Q92134815 | Long-term follow-up of intensive glycaemic control in type 2 diabetes |
| Q88216068 | Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM) |
| Q51246622 | Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. |
| Q26745818 | Management of diabetes mellitus in older people with comorbidities |
| Q30239853 | Management standards for stable coronary artery disease in India |
| Q36820609 | Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes |
| Q48120912 | Non-invasive detection of divergent metabolic signals in insulin deficiency vs. insulin resistance in vivo. |
| Q37226206 | Obesity, diabetes, and length of time in the United States: Analysis of National Health and Nutrition Examination Survey 1999 to 2012. |
| Q57139598 | Organ memory: a key principle for understanding the pathophysiology of hypertension and other non-communicable diseases |
| Q91600278 | Overview and Discussion of the 2017 VA/DoD Clinical Practice Guideline for the Management of Type 2 Diabetes Mellitus in Primary Care |
| Q35684097 | Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet |
| Q41414935 | Paratubular basement membrane insudative lesions predict renal prognosis in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. |
| Q37433043 | Physician perspectives on de-intensifying diabetes medications |
| Q26783199 | Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement |
| Q30374407 | Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. |
| Q26767283 | Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes |
| Q64067428 | Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COhoRtE (DIACORE) study |
| Q90314284 | Post-Trial Sustainability and Scalability of the Benefits of a Medical Home for High-Risk Children with Medical Complexity |
| Q26782607 | Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician |
| Q89932693 | Prediabetes definitions and clinical outcomes - Authors' reply |
| Q40217541 | Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score |
| Q37230872 | Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study |
| Q37069905 | Prevalence and Management of Diabetic Nephropathy in Western Countries |
| Q36420975 | Prevalence of Metformin Use and the Associated Risk of Metabolic Acidosis in US Diabetic Adults With CKD: A National Cross-Sectional Study |
| Q36926126 | Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis |
| Q90182808 | Preventing CKD in Developed Countries |
| Q36770851 | Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-β-d-Glucosaminidase, and Urinary β2-Microglobulin in Patients with Type 2 Diabetes and Biopsy-Proven Diabetic Nephropathy |
| Q64113509 | Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes |
| Q41313094 | Prostaglandin F2α receptor silencing attenuates vascular remodeling in rats with type 2 diabetes |
| Q38442040 | Recent advances in glucose-lowering treatment to reduce diabetic kidney disease. |
| Q36073914 | Relationship between self-reported weight change, educational status, and health-related quality of life in patients with diabetes in Luxembourg |
| Q47149127 | Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). |
| Q89465090 | Renal physiology of glucose handling and therapeutic implications |
| Q92134307 | Risk Factors Before Dialysis Predominate as Mortality Predictors in Diabetic Maintenance Dialysis patients |
| Q42726507 | Should Hemoglobin A1C Be Routinely Measured in Patients with CKD? |
| Q41107308 | Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes |
| Q39123582 | The Application of Genomics in Diabetes: Barriers to Discovery and Implementation |
| Q35914820 | The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease |
| Q47117670 | The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis |
| Q35849463 | The Look AHEAD Trial: Implications for Lifestyle Intervention in Type 2 Diabetes Mellitus |
| Q90539300 | The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE |
| Q38614488 | The effect of SGLT2 inhibitors on cardiovascular events and renal function. |
| Q91012614 | The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes |
| Q34477117 | The health system and population health implications of large-scale diabetes screening in India: a microsimulation model of alternative approaches |
| Q41712441 | The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control. |
| Q37107872 | The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease |
| Q64119903 | The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study |
| Q91856939 | The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study |
| Q64277757 | The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study |
| Q100750541 | The trials and tribulations of determining HbA1c targets for diabetes mellitus |
| Q89963486 | Therapeutic Inertia: Still a Long Way to Go That Cannot Be Postponed |
| Q87722866 | Tightening our understanding of intensive glycaemic control |
| Q38478059 | Update on glycemic control for the treatment of diabetic kidney disease. |
| Q88447753 | Using Shared Decision-Making to Address Possible Overtreatment in Patients at High Risk for Hypoglycemia: The Veterans Health Administration's Choosing Wisely Hypoglycemia Safety Initiative |
| Q39446720 | Vascular complications in diabetes: old messages, new thoughts |
| Q38755360 | Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity |
| Q40619323 | Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. |
Search more.